Table 3.
Strategy | Total Cost (Millions) |
Incremental Cost (Millions) |
Total QALY (Life-Years) |
Incremental QALY |
Incremental Cost- Effectiveness Ratio |
---|---|---|---|---|---|
No intervention | 246.1 | −301.8 | 187,750,960 | −42,240 | 7,146.0 |
Infant vaccination only | 504.9 | −43.0 | 187,786,320 | −6,880 | 6,250.0 |
Sequential HBeAg testing | 544.6 | −3.3 | 187,796,280 | 3,080 | Cost-saving |
Current recommendation | 547.9 | 187,793,200 | Reference | ||
Sequential HBV load testing 108 copies/mL or greater as cutoff |
551.2 | 3.3 | 187,795,280 | 2,080 | 1,582.7 |
Sequential HBV load testing 106 copies/mL or greater as cutoff |
555.9 | 8.0 | 187,796,640 | 3,440 | 2,339.2 |
QALY, quality-adjusted life years; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
A negative incremental cost means less cost; a negative incremental QALY saved means fewer QALYs gained.
Based on a hypothetical 2010 birth cohort of 4 million neonates and 2010 U.S. dollars, both costs and QALYs were discounted at a 3% annual rate. A negative incremental cost means less cost; a negative incremental QALY saved means fewer QALYs gained.